본문 바로가기
[학술저널]

  • 학술저널

박상혁 장철훈 김형회 김신영 이선민 이종윤 김인숙 이은엽 ChulhunLudgerusChang 송문곤 신호진

발행기관의 요청으로 개인이 구매하실 수 없습니다.

표지

북마크 0

리뷰 0

이용수 0

피인용수 0

초록

We evaluated the incidence, clinical characteristics, and prognostic impact of calreticulin (CALR) mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) patients. In all, 48 ET and 14 PMF patients were enrolled, and the presence of CALR mutations was analyzed by direct sequencing. Patients were classified into three subgroups according to Janus kinase 2 (JAK2) V617F and CALR mutation status, and their clinical features and prognosis were compared. CALR mutations were detected in 15 (24.2%) patients, and the incidence increased to 50.0% in 30 JAK2 V617F mutation-negative cases. These included 11 patients with three known mutations (c.1092_1143del [seven cases], c.1154_1155insTTGTC [three cases], and c.1102_1135del [one case]) and 4 patients with novel mutations. ET patients carrying CALR mutation were younger, had lower white blood cell counts, and experienced less thrombosis during follow-up than those carrying JAK2 V617F mutation, while both patient groups showed similar clinical features and prognosis. In ET patients without JAK2 V617F mutation, CALR mutation did not significantly affect clinical manifestation and prognosis. In conclusion, CALR mutation analysis could be a useful diagnostic tool for ET and PMF in 50% of the cases without JAK2 V617F mutations. The prognostic impact of CALR mutations needs further investigation.

목차

등록된 정보가 없습니다.

리뷰(0)

도움이 되었어요.0

도움이 안되었어요.0

첫 리뷰를 남겨주세요.
DBpia에서 서비스 중인 논문에 한하여 피인용 수가 반영됩니다.
인용된 논문이 DBpia에서 서비스 중이라면, 아래 [참고문헌 신청]을 통해서 등록해보세요.
Insert title here